Liquidia Corporation Reports $54.3 Million Revenue and $3.5 Million Net Loss for Q3 2025

Liquidia Corporation reported significant financial developments in its latest 10-Q filing for the quarter ending September 30, 2025. The company generated total revenues of $54.3 million, a substantial increase from $4.4 million in the same period last year. This growth was primarily driven by the launch of YUTREPIA, an inhalation powder for treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD), which began commercialization in June 2025 following FDA approval. Product sales accounted for $51.7 million of the total revenue, while service revenue from a promotion agreement with Sandoz Inc. contributed $2.7 million, down from $4.4 million in the prior year.

Despite the revenue increase, Liquidia reported a net loss of $3.5 million for the quarter, a significant improvement compared to a net loss of $31.0 million in the same quarter of 2024. For the nine months ended September 30, 2025, the net loss was $83.5 million, slightly better than the $89.8 million loss reported for the same period in the previous year. The company’s total expenses rose to $52.6 million for the quarter, up from $33.6 million a year earlier, largely due to increased selling, general, and administrative expenses, which nearly doubled to $40.1 million as the company ramped up its commercialization efforts.

Operationally, Liquidia's headcount has increased as part of its strategy to support the launch of YUTREPIA and the development of its product pipeline, including L606, an investigational formulation of treprostinil. The company is also navigating ongoing litigation with United Therapeutics, which could impact its ability to market YUTREPIA. As of September 30, 2025, Liquidia had cash and cash equivalents of $157.5 million, down from $176.5 million at the end of 2024, reflecting ongoing investments in commercialization and development activities.

Looking ahead, Liquidia remains focused on sustaining the momentum from YUTREPIA's launch while managing its financial resources carefully. The company anticipates continued operating losses as it invests in marketing and clinical trials for its product candidates. Liquidia has indicated that it expects to maintain sufficient cash reserves to meet its obligations for at least the next twelve months, although it acknowledges the inherent uncertainties in achieving sustained revenue growth and the potential need for additional financing in the future. The recent licensing agreement with Vectura Limited, which grants Liquidia rights to develop and commercialize products using Vectura's nebulizer device, is expected to further enhance its product offerings in the hypertension market.